Have you or your loved ones been diagnosed with melanoma?

You may be eligible to participate in a melanoma clinical trial.

Have you or your loved ones been diagnosed with melanoma? You may be eligible to participate in a melanoma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

MELANOMA Clinical Trial in Vinnytsia
NCT02573259 | Phase 1 | Interventional
Pfizer
Sponsored by
Pfizer

Have you or your loved ones been diagnosed with melanoma?

You may be eligible to participate in a melanoma clinical trial.

Have you or your loved ones been diagnosed with melanoma? You may be eligible to participate in a melanoma clinical trial.

Completed

Male & Female

18 Years +

This study has recruited 147 Participants

Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with locally advanced or metastatic melanoma, SCCHN, ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2 Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV) or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or urothelial carcinoma as well as confirm the recommended Phase 2 dose.